Caribou Biosciences (CRBU) Common Equity (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Common Equity data on file, last reported at $102.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $102.0 million, down 53.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.0 million (down 53.04% YoY), and the FY2025 annual result was $122.2 million, down 51.7% from the prior year.
• Common Equity retreated to $102.0 million in Q1 2026 per CRBU's latest filing, from $122.2 million in the prior quarter.
• Over five years, Common Equity peaked at $398.3 million in Q3 2023 and troughed at $102.0 million in Q1 2026.
• A 5-year average of $270.4 million and a median of $281.2 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity soared 1141.77% in 2022, then sank 53.04% in 2026.
• A 5-year view of Common Equity shows it stood at $300.9 million in 2022, then gained by 22.44% to $368.4 million in 2023, then slumped by 31.34% to $253.0 million in 2024, then plunged by 51.7% to $122.2 million in 2025, then fell by 16.5% to $102.0 million in 2026.
• Business Quant data shows CRBU's Common Equity at $102.0 million in Q1 2026, $122.2 million in Q4 2025, and $141.8 million in Q3 2025.